Chronic myeloid leukaemia (CML) incidence statistics

Cases

New cases of chronic myeloid leukaemia each year, 2017-2019 average, UK

 

Proportion of all cases

Percentage chronic myeloid leukaemia is of total cancer cases, 2017-2019, UK

 

Age

Peak rate of chronic myeloid leukaemia cases, 2017-2019, UK

 

Trend over time

Change in chronic myeloid leukaemia incidence rates since the early 1990s, UK

 

Chronic myeloid leukaemia accounted for less than 1% of all new cancer cases in the UK in 2017-2019.[1-4]

In females in the UK, chronic myeloid leukaemia accounted for less than 1% of all new female cancer cases. In males in the UK, it accounted for less than 1% of all new male cancer cases).

45% of chronic myeloid leukaemia cases in the UK are in females, and 55% are in males.

Chronic myeloid leukaemia incidence rates (European age-standardised (AS) rate Open a glossary item) for persons are similar to the UK average in all the UK constituent countries.

Chronic Myeloid Leukaemia (C92.1), Average Number of New Cases Per Year, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2017-2019

  England Scotland Wales Northern Ireland UK
Female Cases 315 34 15 10 373
Crude Rate 1.1 1.2 0.9 1.0 1.1
AS Rate 1.1 1.2 0.9 1.1 1.1
AS Rate - 95% LCL 1.0 1.0 0.6 0.7 1.0
AS Rate - 95% UCL 1.2 1.4 1.1 1.5 1.2
Male Cases 392 39 19 13 464
Crude Rate 1.4 1.5 1.2 1.4 1.4
AS Rate 1.6 1.6 1.3 1.7 1.5
AS Rate - 95% LCL 1.5 1.3 0.9 1.2 1.5
AS Rate - 95% UCL 1.6 1.9 1.6 2.2 1.6
Persons Cases 707 73 34 23 836
Crude Rate 1.3 1.3 1.1 1.2 1.3
AS Rate 1.3 1.4 1.1 1.4 1.3
AS Rate - 95% LCL 1.3 1.2 0.9 1.0 1.3
AS Rate - 95% UCL 1.4 1.5 1.3 1.7 1.4

95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate Open a glossary item

References

  1. England data were provided by the National Cancer Registration and Analysis Service (NCRAS), part of the National Disease Registration Service (NDRS) in NHS England, on request through the Office for Data Release, January 2023. Similar data can be found here: https://www.cancerdata.nhs.uk/ 

  2.  Northern Ireland data were provided by the Northern Ireland Cancer Registry (NICR) on request, October 2021. Similar data can be found here:http://www.qub.ac.uk/research-centres/nicr/. 

  3. Welsh data were published by the Welsh Cancer Intelligence and Surveillance Unit (WCISU), Health Intelligence Division, Public Health Wales https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-reporting-tool-official-statistics/ June 2022. 

  4. Scotland data were provided by the Scottish Cancer Registry, Public Health Scotland (PHS) on request, May 2021. Similar data can be found here: https://publichealthscotland.scot/publications/show-all-releases?id=20468

About this data

Data is for UK, 2017-2019, ICD-10 C92.1.

Last reviewed:

In the UK in 2017-2019, on average each year around a quarter of new cases (24%) were in people aged 75 and over.[1-4]

Age-specific incidence rates rise gradually from birth, more steeply for males than females. The highest rates are in the 90+ age group for females and males.

Incidence rates are significantly lower for females than males in a number of (mainly older) age groups. The gap is widest at age 80 to 84, when the age-specific incidence rate is 1.8 times lower for females than males.

Chronic Myeloid Leukaemia (C92.1), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2017-2019

For chronic myeloid leukaemia, like most cancer types, incidence increases with age. This largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

 

See also

Chronic myeloid leukaemia mortality statistics by age

Leukaemia (all subtypes combined) incidence statistics

Cancer incidence statistics by age for all cancers

References

  1. England data were provided by the National Cancer Registration and Analysis Service (NCRAS), part of the National Disease Registration Service (NDRS) in NHS England, on request through the Office for Data Release, January 2023. Similar data can be found here: https://www.cancerdata.nhs.uk/ 

  2.  Northern Ireland data were provided by the Northern Ireland Cancer Registry (NICR) on request, October 2021. Similar data can be found here:http://www.qub.ac.uk/research-centres/nicr/. 

  3. Welsh data were published by the Welsh Cancer Intelligence and Surveillance Unit (WCISU), Health Intelligence Division, Public Health Wales https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-reporting-tool-official-statistics/ June 2022. 

  4. Scotland data were provided by the Scottish Cancer Registry, Public Health Scotland (PHS) on request, May 2021. Similar data can be found here: https://publichealthscotland.scot/publications/show-all-releases?id=20468

About this data

Data is for UK, 2017-2019, ICD-10 C92.1.

Last reviewed:

Chronic myeloid leukaemia European age-standardised (AS) Open a glossary item incidence rates for females and males combined decreased by 26% in the UK between 1993-1995 and 2017-2019.[1-4] The decrease was larger in males than in females.

For females, chronic myeloid leukaemia AS incidence rates in the UK decreased by 20% between 1993-1995 and 2017-2019. For males, chronic myeloid leukaemia AS incidence rates in the UK decreased by 35% between 1993-1995 and 2017-2019.

Over the last decade in the UK (between 2007-2009 and 2017-2019), chronic myeloid leukaemia AS incidence rates for females and males combined remained stable. In females AS incidence rates increased by 16%, and in males rates remained stable.

Chronic Myeloid Leukaemia (ICD-10 C92.1), European Age-Standardised Incidence Rates, Persons Population, 1993 to 2019

Chronic myeloid leukaemia incidence rates have varied between age groups in females and males combined in the UK since the early 1990s.[1-4] Rates in 0-24s have remained stable, in 25-49s have increased by 46%, in 50-59s have remained stable, in 60-69s have remained stable, in 70-79s have decreased by 46% and in 80+s have decreased by 63%.

Chronic Myeloid Leukaemia (ICD-10 C92.1), European Age-Standardised Incidence Rates per 100,000 Persons Population, By Age, UK, 1993-2019

For chronic myeloid leukaemia there are few established risk factors, therefore increasing incidence in the 1980s and 1990s may largely reflect improvements in diagnosis and data recording, plus changes in the definition of CML.

References

  1. England data were provided by the National Cancer Registration and Analysis Service (NCRAS), part of the National Disease Registration Service (NDRS) in NHS England, on request through the Office for Data Release, January 2023. Similar data can be found here: https://www.cancerdata.nhs.uk/ 

  2.  Northern Ireland data were provided by the Northern Ireland Cancer Registry (NICR) on request, October 2021. Similar data can be found here:http://www.qub.ac.uk/research-centres/nicr/. 

  3. Welsh data were published by the Welsh Cancer Intelligence and Surveillance Unit (WCISU), Health Intelligence Division, Public Health Wales https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-reporting-tool-official-statistics/ June 2022. 

  4. Scotland data were provided by the Scottish Cancer Registry, Public Health Scotland (PHS) on request, May 2021. Similar data can be found here: https://publichealthscotland.scot/publications/show-all-releases?id=20468

About this data

Data is for UK, 1993-2019, ICD-10 C92.1.

Last reviewed:

Chronic myeloid leukaemia incidence rates (European age-standardised (AS) rates Open a glossary item) in England in females are similar in the most deprived quintile compared with the least, and in males are similar in the most deprived quintile compared with the least (2013-2017).[1]

See also

Data table: Cancer incidence rates and excess cases by cancer type in England

Incidence by deprivation for all cancer types combined

Chronic myeloid leukaemia mortality by deprivation  (not directly comparable with incidence by deprivation)

Cancer incidence by deprivation for Scotland

Cancer incidence by deprivation for Wales

Cancer incidence by deprivation for Northern Ireland

References

  1. Calculated by the Cancer Intelligence Team at Cancer Research UK, April 2020. Based on method reported in National Cancer Intelligence Network Cancer by Deprivation in England Incidence, 1996-2010 Mortality, 1997-2011 . Using cancer incidence data 2013-2017 (Public Health England) and population data 2013-2017 (Office for National Statistics) by Indices of Multiple Deprivation 2015 income domain quintile, cancer type, sex, and five-year age band.

About this data

Data is for England, 2013-2017, ICD-10 C92.1.

Last reviewed:

An estimated 6,000 people who had been diagnosed with chronic myeloid leukaemia (CML) between 1991 and 2010 were alive in the UK at the end of 2010.[1]

See also

Chronic myeloid leukaemia (CML) cancer incidence statistics by sex and UK country

What is prevalence?

References

  1. Macmillan Cancer Support and National Cancer Registration and Analysis Service. Cancer Prevalence UK Data Tables. London: NCRAS; 2015.

About this data

Data is for: Great Britain (1991-2010) and Northern Ireland (1993-2010), ICD-10 C92.1

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Cancer stats explained

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate Online 

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.